LM, my take on CYDY at this time is that I am not sure how RIGHT I am about CYDY's potential upside, but I am reasonably certain that I can't be but so WRONG, at this point, regarding the potential downside of this investment over the medium term.
My expectation is that there is well over a 90% change of approval in HIV combination therapy. That being the case, even if all else fails, CYDY would have a viable product to sell into a captive (if limited) market. Based on that, I expect CYDY will generate enough revenue, over the next 2 years, sufficient to support a market cap resulting in a share price AT LEAST somewhere near my current average (.515), even if further dilution were to be required to get there from here.
It's my belief in the lack of potential downside (both in probability and degree) that makes me willing to extend myself to an uncomfortable position in this investment in order to take advantage of the frankly absurd potential upside available from mono HIV/cancer/etc.
Good luck to us all!
Market Data 
Markets 
AI
